Click Therapeutics

Data from the clinical trial might give patients a new option for treating migraines.

The new smartphone app, Rejoyn, will deliver treatment to patients taking antidepressant medication aimed at enhancing cognitive control of emotion.

Boehringer Ingelheim and Click Therapeutics initiate clinical trial on PDTx treatment for schizophrenia and Akili's EndeavorRx shows promise for adults with ADHD.

Click Therapeutics has begun a clinical trial for its episode migraine digital therapeutic, and Digital Diagnostics is offering its AI-backed diabetic retinopathy screening at select Labcorp locations.

Austin Speier, chief strategy officer at Click Therapeutics, discusses the company's expanded partnership with Boehringer Ingelheim.

The companies first partnered in 2020 to develop a prescription digital therapeutic for schizophrenia. They said a treatment strategy for the condition "would benefit from a multi-product approach."

Click Therapeutics received FDA Breakthrough Device Designation for a prescription digital therapeutic for episodic migraine, and Superior HealthPlan announced a home care partnership with MedArrive and Brave Health.

Also: RPM company Blue Spark Technologies brought in $40 million in IP-backed debt financing, and Click Therapeutics secured a $15 million loan.

Also: LifeStation and Papa collaborate on a social connectedness effort. 

This news comes roughly a year after the company signed a $500 million deal with Boehringer Ingelheim.